OWP Pharmaceuticals Logo
Subvenite® (lamotrigine) Oral Suspension Logo

Cookie Policy

Effective Date: September 21, 2026

This Cookie Policy explains how OWP Pharmaceuticals, Inc. (“OWP,” “we,” “us,” or “our”) uses cookies and similar technologies when you visit subvenite.com (the “Website”).

What Are Cookies?

Cookies are small text files stored on your device when you visit a website. Cookies and similar technologies, such as pixels, tags, scripts, and local storage, can help websites function, remember preferences, understand how visitors use a website, and protect against fraud or misuse.

How We Use Cookies

We may use the following categories of cookies and similar technologies:

  • Essential technologies: These support core Website functions, security, network management, and accessibility.
  • Analytics technologies: These help us understand aggregate Website traffic, page usage, navigation patterns, device and browser characteristics, and Website performance.
  • Functional technologies: These may remember certain choices or support features provided through the Website.
  • Embedded-content technologies: Third-party content, including videos, may place or access cookies when you interact with it.
  • Security technologies: Services such as Google reCAPTCHA may collect device and interaction information to help distinguish legitimate users from automated activity.
  • Email-form technologies: Constant Contact may use technologies associated with the healthcare-professional email-update form and the delivery and measurement of requested email communications.

Google Analytics and Google Tag Manager

We use Google Analytics and Google Tag Manager to support aggregate Website measurement and administration. Information collected may include your approximate location, IP address, device and browser information, referring page, pages visited, interactions, and approximate visit duration.

OWP uses these services for aggregate Website measurement and does not intentionally use Website tracking information for targeted advertising or remarketing. Google may process information according to its own privacy terms. Google Tag Manager facilitates the operation of other Website technologies and does not itself determine how the information is used.

Embedded Videos

The Website may contain videos hosted by YouTube or another third-party platform. When you load or interact with embedded content, the provider may receive information about your device, browser, IP address, Website activity, or account status. These technologies are controlled by the applicable provider.

Google reCAPTCHA

We may use Google reCAPTCHA to protect forms and Website functions from spam, abuse, and automated submissions. reCAPTCHA may collect hardware and software information and interaction data for security purposes. Its use is subject to Google’s applicable privacy policy and terms.

Managing Cookies

Most browsers allow you to block, delete, or receive warnings about cookies through their settings. Restricting cookies may affect the availability or operation of certain Website features. Browser controls may not affect all similar technologies or information already collected.

You may obtain information about Google Analytics controls, including Google’s browser opt-out tools, directly from Google. Controls offered by third parties are governed by those parties and may change without notice.

Do Not Track and Preference Signals

Some browsers transmit “Do Not Track” or other preference signals. Because no uniform response standard applies in every context, the Website may not respond to every signal. We will recognize legally required browser-based opt-out preference signals to the extent required by applicable law.

Changes to This Policy

We may update this Cookie Policy as our Website, technologies, or legal obligations change. The revised policy will be posted with an updated effective date.

Contact Us

If you have questions about this Cookie Policy, contact:

OWP Pharmaceuticals, Inc.
701 Warrenville Road, Suite 200
Lisle, IL 60532
Telephone: 1-800-273-6729
Email: info@owppharma.com

Subvenite® (lamotrigine) Oral Suspension logo icon

© 2025 OWP Pharmaceuticals, Inc. All rights reserved.
Naperville, IL 60563. Developed in USA.

You are now leaving Subvenite.com

Links to all outside sites are provided as a resource to our visitors. OWP Pharmaceuticals accepts no responsibility for the content of the sites that are not owned and operated by OWP Pharmaceuticals.

Continue
Cancel

You are now leaving Subvenite.com

Links to all outside sites are provided as a resource to our visitors. OWP Pharmaceuticals accepts no responsibility for the content of the sites that are not owned and operated by OWP Pharmaceuticals.

Continue
Cancel
Important Safety Information & Resources

WARNING: SERIOUS SKIN RASHES

See full prescribing information for complete boxed warning.

Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine, the active ingredient in SUBVENITE. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:

  • coadministration with valproate.
  • exceeding recommended initial dose of SUBVENITE.
  • exceeding recommended dose escalation for SUBVENITE.
  • presence of the HLA-B*1502 allele. (5.1)

Benign rashes are also caused by lamotrigine, the active ingredient in SUBVENITE; however, it is not possible to predict which rashes will prove to be serious or life threatening. SUBVENITE should be discontinued at the first sign of rash, unless the rash is clearly not drug related. (5.1)
 

SUBVENITE is indicated for:
Epilepsy—adjunctive therapy in patients aged 2 years and older:

  • partial-onset seizures
  • primary generalized tonic-clonic (PGTC) seizures
  • generalized seizures of Lennox-Gastaut syndrome. (1.1)
 

Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. (1.1)

Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)

Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of SUBVENITE in the acute treatment of mood episodes has not been established.

DOSAGE AND ADMINISTRATION

  • Dosing is based on concomitant medications, indication, and patient age. (2.1, 2.2, 2.3, 2.4)
  • To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. (2.1, 16)
  • Do not restart SUBVENITE in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. (2.1, 5.1)
  • Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing products, including oral contraceptives. (2.1, 5.9)
  • Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). (2.1, 5.10)
 

Epilepsy:
Adjunctive therapy—See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12 years. (2.2)
Conversion to monotherapy—See Table 4. (2.3)
Bipolar disorder: See Tables 5 and 6. (2.4)

DOSAGE FORMS AND STRENGTHS

  • Oral Suspension: 10 mg/mL (3)
 

CONTRAINDICATIONS

Hypersensitivity to the drug or its ingredients. (Boxed Warning, 4)

WARNINGS & PRECAUTIONS

  • Life-threatening serious rash and/or rash-related death: Discontinue at the first sign of rash, unless the rash is clearly not drug related. (Boxed Warning, 5.1).
  • Hemophagocytic lymphohistiocytosis: Consider this diagnosis and evaluate patients immediately if they develop signs or symptoms of systemic inflammation. Discontinue lamotrigine if an alternative etiology is not established. (5.2)
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: Discontinue if no alternate etiology. (5.3)
  • Cardiac rhythm and conduction abnormalities: Can cause cardiac rhythm and conduction abnormalities, particularly in patients with underlying cardiac disorders or arrhythmias. (5.4)
  • Blood dyscrasias (e.g., neutropenia, thrombocytopenia, pancytopenia): May occur, either with or without an associated hypersensitivity syndrome. Monitor for signs of anemia, unexpected infection, or bleeding. (5.5)
  • Suicidal behavior and ideation: Monitor for suicidal thoughts or behaviors. (5.6)
  • Aseptic meningitis: Monitor for signs of meningitis. (5.7)
  • Medication errors due to product name confusion: Strongly advise patients to visually inspect the product to verify the received drug is correct. (5.8, 16, 17)
 

ADVERSE REACTIONS

Epilepsy: Most common adverse reactions (incidence ≥10%) in adults were dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, pharyngitis, and rash. Additional adverse reactions (incidence ≥10%) reported in children included vomiting, infection, fever, accidental injury, diarrhea, abdominal pain, and tremor. (6.1)

Bipolar Disorder: Most common adverse reactions (incidence >5%) in adults were nausea, insomnia, somnolence, back pain, fatigue, rash, rhinitis, abdominal pain, and xerostomia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact OWP Pharmaceuticals Inc. at 1-800-273-6729 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Valproate increases lamotrigine concentrations more than 2-fold. (7, 12.3)
  • Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin decrease lamotrigine concentrations by approximately 40%. (7, 12.3)
  • Estrogen-containing oral contraceptives decrease lamotrigine concentrations by approximately 50%. (7, 12.3)
  • Protease inhibitors lopinavir/ritonavir and atazanavir/lopinavir decrease lamotrigine exposure by approximately 50% and 32%, respectively. (7, 12.3)
  • Coadministration with organic cationic transporter 2 substrates with narrow therapeutic index is not recommended (7, 12.3)
 

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Based on animal data may cause fetal harm. (8.1)
  • Hepatic impairment: Dosage adjustments required in patients with moderate and severe liver impairment. (2.1, 8.6)
  • Renal impairment: Reduced maintenance doses may be effective for patients with significant renal impairment. (2.1, 8.7)
 

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Please refer to the full Prescribing Information for SUBVENITE at www.subvenite.com.

08/2026
Resources